Moreover, mutations observed in ErbB4 in non-small cell lung cancer patients experimentally lead to changes in ErbB2-ErbB4 heterodimer signaling promoting cell proliferation but not differentiation [9], and to increased phosphorylation likely because of stabilization of the ErbB4 active dimer state [10]. Here, ERBB4 is linked to non-small cell lung carcinoma.